Cerus Corporation.
CERS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System. This system is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites, as well as reducing the risk...Show More
Better Health for All
30
Cerus Corporation's core product, the INTERCEPT Blood System, delivers transformative health benefits by reducing the risk of transfusion-transmitted infections through the inactivation of various pathogens, treating 2.5 million platelet units annually.
1
The company demonstrates excellent risk transparency by explicitly disclosing in its package inserts and technical documents that certain pathogens, such as HAV, HEV, B19, poliovirus, and Bacillus cereus spores, are resistant to the INTERCEPT process.
2
Fair Money & Economic Opportunity
0
Cerus Corporation is a biomedical products company, not a financial institution.
1
The provided articles focus exclusively on the company's internal diversity, equity, and inclusion (DE&I) initiatives, detailing employee demographics and promotion rates by gender, race, disability, and veteran status, as well as commitment to pay equity.
2
There is no evidence in the articles regarding financial products, lending services, customer financial data, or any other activities related to the 'Fair Money & Economic Opportunity' value.
3
Consequently, all KPIs under this value are omitted due to a complete lack of relevant data.
Fair Pay & Worker Respect
30
For the 2024 fiscal year, Cerus Corporation's CEO-to-median employee pay ratio was 15:1.
1
This was calculated based on the CEO's total compensation of $2,975,617 and the median employee pay of $197,931.
2
This ratio is lower than the 2023 average CEO-to-worker pay ratio for S&P 500 companies, which was 268-to-1.
3
Fair Trade & Ethical Sourcing
-40
Cerus Corporation's 2022/2023 country-of-origin inquiry for tin in the INTERCEPT Illuminator found no evidence of conflict minerals.
1
However, a more detailed conflict minerals report for the Illuminator product indicates that 15% of its components have an unknown origin or undetermined conflict status.
2
Additionally, 49% of components originate from covered countries, and 5% contain conflict minerals from non-covered countries.
3
The company states it is unable to definitively determine the origin of conflict minerals in the Illuminator due to supply chain complexity and reliance on third-party supplier information, and has limited ability to verify the accuracy of supplier information.
4
This means that 69% (49% + 15% + 5%) of components are either from covered countries, of unknown origin, or from non-covered countries, indicating a significant share of spend on materials with potential risk or unknown provenance.
Honest & Fair Business
-40
Cerus Corporation has a Code of Business Conduct and Ethics available on its website, which includes a whistle-blower policy with an anonymized reporting system and protection against retaliation.
1
Procedures are in place to address complaints regarding accounting, internal accounting controls, or auditing matters.
2
The company also has an anti-corruption policy that emphasizes compliance with the FCPA and international business laws, specifically prohibiting bribery.
3
An Incentive Compensation Recoupment Policy has been adopted to address potential conflicts of interest.
4
The company uses an independent external auditor, Ernst & Young LLP, and relies on third-party manufacturers for components, but the extent of independent verification of ethical claims is not specified beyond the financial audit.
5
Kind to Animals
-60
Cerus Corporation has no explicit animal testing policy mentioned in the provided articles.
1
The company reported conducting a pre-clinical study that evaluated the use of T-cells in an animal bone marrow transplant model, confirming animal usage for testing.
2
The number of animals used in this study is not specified, but the company has reported animal usage for testing.
3
No War, No Weapons
0
No evidence available to assess Cerus Corporation on No War, No Weapons.
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative data points or concrete evidence to assess Cerus Corporation against any of the Planet-Friendly Business KPIs.
1
discusses general corporate climate actions but does not mention Cerus Corporation.
2
, from Cerus's own website, explicitly states that no quantitative data or specific ESG metrics are provided, only a vision statement and commitment to sustainability, which are not considered actionable evidence for scoring.
Respect for Cultures & Communities
0
No evidence available to assess Cerus Corporation on Respect for Cultures & Communities.
Safe & Smart Tech
0
Cerus Corporation's Privacy Policy, effective January 1, 2023, details comprehensive user rights, including the ability to access, review, update, and request deletion of information, opt-out of marketing and targeted advertising, manage cookies, and exercise data portability, restriction, objection, and consent withdrawal.
1
The company states it retains data only as long as necessary for the original purpose, including legal, accounting, and reporting requirements, and may delete or anonymize data in some cases.
2
The policy also references EU GDPR and provides specific rights and notices for California residents under the CCPA, and uses Standard Contractual Clauses for cross-border data transfers.
3
There are no documented incidents of unauthorized data use.
Zero Waste & Sustainable Products
0
The provided article focuses on the company's general mission and commitment to Environmental, Social, and Governance (ESG) practices.
1
It does not contain any specific quantitative data or concrete facts relevant to the Zero Waste & Sustainable Products ethical value, therefore no KPIs can be scored.
2